José Luis Ramírez

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Oncology, Standard Chemotherapy, Randomised Phase 3 +8

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

Luping Lin, Amit J. Sabnis, Elton Chan et al. · Nature Genetics · 2015 · 548 citations · Full text

Medicine, Mek-targeted Cancer Therapies, Hippo Effector Yap +8

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

Imane Chaib, Niki Karachaliou, Sara Pilotto et al. · JNCI Journal of the National Cancer Institute · 2017 · 216 citations · Full text

Molecular karyotype of clone CL Brener chosen for the Trypanosoma cruzi Genome Project

Maria Isabel Nogueira Cano, Arthur Gruber, Martı́n Vázquez et al. · Molecular and Biochemical Parasitology · 1995 · 150 citations

Biology, Genome Study, Comparative Genomics +8

O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.

Carmen Balañá, José Luis Ramírez, Miquel Tarón et al. · PubMed · 2003 · 147 citations